Skip to main content

Tenors get extended as structurers face poor market conditions

Maturities for US structured products get stretched and Barclays issues a reverse convertible with a high risk rating

Tenors in the latest issuance have been stretched, possibly due to tough structuring conditions resulting from low rates and volatility.

HSBC has issued a leveraged product with a 10-year tenor, which is almost unheard of for retail equity-linked products. The product tracks the S&P 500 and has a participation rate of 180-200%. If the downside barrier of 50% is breached capital will be lost at the rate of 1:1. The product has a relatively low riskmap score of 6.3 and an overall score of 3.8.

Other products in the latest offerings that feature long tenors are a Goldman Sachs six-year principal-protected product and several with four-year tenors.

Products in the US market usually have maturities of up to two years unless they are principal protected, but even then they tend to be five-year products at most, not the six years offered by Goldman Sachs.

There are a few reverse convertibles from Barclays in the latest offering. One, which tracks the stock of Celanese has a riskmap rating of 10, the highest which can be awarded by Future Value Consultants. The six-month product provides a return of 8.1-10.6% and has an 80% barrier against falls in the underlying. The structure is fairly standard for a reverse convertible so the high score is likely to be based on the volatility of the underlying stock.

us-issuance-110704

Source: FVC and SEC filings
For access to analysis of the US structured products market: www.structurededge.com

 

 

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here